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Glioblastoma multiforme (GBM) is the most commonly occurring primary brain cancer in adults, in
whom its highly infiltrative cells prevent total surgical resection, often leading to tumor recurrence and
patient death. Our group has discovered a gene therapy approach for GBM that utilizes high-capacity
‘‘gutless’’ adenoviral vectors encoding regulatable therapeutic transgenes. The herpes simplex type 1-
thymidine kinase (TK) actively kills dividing tumor cells in the brain when in the presence of the
prodrug, ganciclovir (GCV), whereas the FMS-like tyrosine kinase 3 ligand (Flt3L) is an immune-
stimulatory molecule under tight regulation by a tetracycline-inducible ‘‘Tet-On’’ activation system that
induces anti-GBM immunity. As a prelude to a phase I clinical trial, we evaluated the safety and efficacy
of Food and Drug Administration (FDA)–approved doses of the tetracycline doxycycline (DOX) allo-
metrically scaled for rats. DOX initiates the expression of Flt3L, which has been shown to recruit
dendritic cells to the brain tumor microenvironment—an integral first step in the development of an-
titumor immunity. The data revealed a highly safe profile surrounding these human-equivalent doses of
DOX under an identical therapeutic window as proposed in the clinical trial. This was confirmed
through a neuropathological analysis, liver and kidney histopathology, detection of neutralizing anti-
bodies, and systemic toxicities in the blood. Interestingly, we observed a significant survival advantage
in rats with GBM receiving the 300mg/day equivalent dosage of DOX versus the 200mg/day equivalent.
Additionally, rats rejected ‘‘recurrent’’ brain tumor threats implanted 90 days after their primary brain
tumors. We also show that DOX detection within the plasma can be an indicator of optimal dosing of
DOX to attain therapeutic levels. This work has significant clinical relevance for an ongoing phase I
clinical trial in humans with primary GBM and for other therapeutic approaches using Tet-On trans-
activation system in humans.
INTRODUCTION
GLIOBLASTOMA MULTIFORME (GBM) is a primary ma-
lignant brain cancer in adults with a dismal prog-
nosis of 15–21 months.1 Therapeutic standard of
care includes surgical resection, chemotherapy, and
radiotherapy. Nevertheless, in spite of aggressive
treatment regimes, these diffuse, invasive, and
heterogeneous tumors invariably recur, ultimately
resulting in the death of patients. Thus, there is an
urgent need to develop novel and more efficacious
therapeutic options.
Gene therapy has become an attractive thera-
peutic modality for cancer; improvements in vector
safety and specificity make this approach readily
translatable to the clinic.2–4 Replication-deficient
first-generation adenoviral vectors (Ads) lacking the
E1 gene, while effective at eliciting transgene ex-
pression, maintain low levels of viral gene expres-
*Correspondence: Dr. Maria G. Castro, Department of Neurosurgery, The University of Michigan School of Medicine, MSRB II, RM 4570C, 1150 West Medical Center Drive,
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sion. The result is an adaptive immune response
against the vector leading to transient transgene
expression. In recent years, safer vectors have
been developed by removing all viral coding se-
quences, thereby decreasing toxicities associated
with inflammation as well as preventing immune
detection by the immune system of the host.5–7
These vectors have been termed ‘‘high-capacity,’’
‘‘helper-dependent,’’ or ‘‘gutless’’ adenoviral vec-
tors (HC-Ads). Finally, transgene expression dri-
ven from viral vectors can now be regulated by
transcriptional ‘‘activators,’’ which can be used to
control therapeutic transgene expression. For ex-
ample, the Tet-On transactivation system can be
turned ‘‘on’’ in the presence doxycycline (DOX),
and switched ‘‘off’’ in its absence.7–12
To address GBM recurrence, we developed a
novel combined gene therapy strategy utilizing
the HC-Ads encoding the herpes simplex type 1-
thymidine kinase (TK) transgene, which induces
apoptosis in dividing cells in the presence of the
prodrug, ganciclovir (GCV), and the FMS-like ty-
rosine kinase 3 ligand (Flt3L) transgene under tight
regulation by the Tet-On transactivation system.13–
24 Flt3L has been shown to recruit dendritic cells
(DCs) to the site ofTK-mediated tumorkillingwhere
they bind to thehigh-mobility-groupbox 1 (HMGB1)
protein, an alarmin released by dying GBM cells
within the tumor microenvironment, acting as an
endogenous ligand for Toll-like receptor 2 (TLR2) on
DCs.21,22Oncebound toHMGB1, theseDCsmigrate
to the draining lymph nodes to prime CD4+ T-cells
that in turn activate CD8 T-cells. We have shown
that this adaptive immune response elicits long-
term immunity in rats that not only eliminates large
primary brain tumors, but also overcomes new tu-
mor challenges in the opposite brain hemisphere,
simulating tumor recurrence.19,20,22,24
Before the implementation of HC-Ad-mediated
gene therapy inGBMpatients, we sought to identify
a dose of DOX that would be both efficacious and
safe for clinical use. Despite the safety and accepted
use of DOX as an antibiotic to treat infections in
patients, the application of DOX as an activator of
gene transcription via the Tet-On regulatable pro-
moter system is not yet approved for use in humans.
Thus, this would be an ‘‘off-label’’ use for this drug.
Therefore, we assessed the DOX dose needed to
elicit transgene expression from the Tet-On pro-
moter system encoded within the HC-Ads and also
the efficacy of the DOX-dependent therapy in in-
creasing survival in GBM tumor-bearing rodents.11
DOX is an antibiotic used to treat various types of
infections because of its specificity for inhibiting
bacterial protein synthesis.25 When testing the
therapeutic efficacy of HC-Ad-TK + HC-Ad-TetOn-
Flt3L in the preclinical studies, DOX was adminis-
tered in rat chow at a concentration of 2,000 parts
per million (ppm). However, converting these doses
to the human equivalent yields levels of DOX that
could be considered unsafe for human use. There-
fore, we elected to lower the dosage further to ana-
lyze the three most commonly used FDA-approved
dosages of DOX (100, 200, and 300mg/day) using the
average adult human weight of 70kg.26 This study
allowed us to determine the efficacy of the Tet-On
transcriptional activation system in the presence of
a significantly lower dose of DOX, and also the safety
of such doses when used within an identical clini-
cal therapeutic window of one month. Additionally,
demonstrating that the aforementioned doses of
DOX were effective at inducing expression of the
Flt3L transgene in a species with a complex immune
system with similarities to the human immune sys-
tem was essential in establishing the translation
application of this therapeutic approach in patients.8
In this study, we investigated the efficacy of
the DOX-driven therapy at improving survival
in tumor-bearing rats and analyzed expression of
Flt3L within the tumor microenvironment using
human-equivalent doses of DOX (100, 200, and
300mg/day assuming a 70kg weight). In surviving
animals, we assessed the impact of these human-
equivalent doses on neurological, hepatic, renal,
and hematological safety. Finally, we assessed the
ability of the viral therapy to generate immunolog-
ical memory in animals bearing intracranial tu-
mors. Our results show that allometrically scaled
doses of DOX, that is, equivalent doses to the ones
recommended for use in humans to treat infections,
can safely turn ‘‘on’’ Flt3L expression from the HC-
Ad-TetOn-Flt3L vector in rodents. Our data war-
rant the use of DOX at doses that have previously
been approved by the FDA for the treatment of in-
fections in humans in an ‘‘off-label’’ application of
this drug for the treatment of GBM. It also affirms
the importance of DOX in eliciting sufficient levels
of Flt3L expression to elicit immunological memory
in order to block tumor recurrence. This work has
significant translational relevance for our own up-
coming clinical trial as well as for other researchers
interested in implementing the Tet-On transcrip-
tional activation-dependent expression of thera-
peutic transgenes within the brain.
MATERIALS AND METHODS
Animals
Adult male Lewis rats (200–300 g; Harlan)
were kept in controlled conditions of light (12 hr
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light–dark cycles) and temperature (20–25C).
Rats received water and standard rodent chow ad
libitum. All animal procedures were carried out in
accordance with NIH guidelines for the care and
use of laboratory animals and approved by the
University of Michigan Unit for Laboratory Ani-
mal Medicine.
Stereotactic intracranial injections
Three thousand CNS-1 tumor cells were injected
into the striatum using a 5 ll Hamilton syringe
fitted with a 26-gauge needle. The stereotactic co-
ordinates were 1.0mm anterior and 3.0mm lateral
to the bregma; the injection volume of 1.0ll was
delivered -4.5mm from the dura. Re-challenged
rats, along with 3 age-matched control rats re-
ceived intracranial injections of 3,000CNS-1 tumor
cells 90 days after gene therapy using the injection
procedure and stereotactic coordinates described
above into the contralateral hemisphere. Rats were
intracranially injected with 1 ·109 viral particles
(vp) of HC-Ad-TetOn-Flt3L into the striatum. The
vector was injected in a final volume of 1.5ll of
saline using a 5 ll Hamilton syringe fitted with 26-
gauge needle. The stereotactic coordinates were
1.0mm anterior and 3.0mm lateral to the bregma;
the injection volume of 1.5ll was delivered in 3
locations (0.5 ll each) at -5.0, -4.5, and -4.0mm
from the dura. The appropriate dose of DOX (water
for the control animals) was administered to each
animal every 12hr for 1 month as described below.
High-capacity adenoviral vector
Details of the molecular characterization, res-
cue, and amplification of the HC-Ad vector were
published previously.11,27–33
Allometric dosing of DOX
Allometric doses of DOX for rats were calculated
by dividing the human DOX dose by the average
humanweight of 70kg, and thenmultiplying by the
allometric conversion factor of seven.34 This number
was calculated by taking into account differences in
metabolic rate, pharmacokinetics, and body surface
area betweenhumans and rats. Therefore, theFDA-
approved 300mg dose of DOX in humans is equiv-
alent to 30mg/kg in the rat (see calculations in
Supplementary Fig. S1; Supplementary Data are
available online at www.liebertpub.com/hgtb). Si-
milarly, 200 and 100mg doses of DOX in humans
are equivalent to 20 and 10mg/kg, respectively, in
the rat. In the safety study, in order to express the
Flt3L transgene, we prepared suspensions of the
DOX solution (doxycycline hyclate; Sigma-Aldrich;
Cat. # D9891) in H2O and administered the appro-
priate dose via oral gavage twice daily, 2 days before
HC-Ad vector delivery (day -2), and lasting until
28 days after HC-Ad vector delivery. To create the
10mg/ml oral gavage solution, 500mg DOX was
added to 50mlMilli-QH2O. The solution was stored
at 4C in the dark and prepared fresh every 5 days.
Ganciclovir administration
Rats were administered 25mg/kg of the prodrug,
GCV (Roche Laboratories), via intraperitoneal (IP)
injection from the day of tumor implantation twice
daily for 10 days. To prepare the 7mg/ml stock so-
lution, 20ml of Milli-Q H2O was added to 250mg of
GCV, and pH was adjusted to 12 using 1 M NaOH
such that the solution became clear. Next, the pH
was lowered to 11 using 1 M HCl and Milli-Q H2O
was added to obtain a final volume of 35.71ml. The
solution was stored at -20C.
Perfusion and tissue harvesting
Rats were anesthetizedwith ketamine (75mg/kg,
IP) and dexmedetomidine (0.25mg/kg, IP) be-
fore perfusion with oxygenated Tyrode’s solution
(132 nMNaCl, 1.8mM CaCl2, 0.32mMNaH2PO4,
5.56mM glucose, 11.6mM NaHCO3, 2.68mM KCl,
0.1U/ml heparin; pH 7.4) followed by fixation
with 4% paraformaldehyde (4% paraformalde-
hyde, 137mMNaCl, 2.7mMKCl, 10mM phosphate
buffer; pH 7.4). Brains were post-fixed in 4% para-
formaldehyde for 3 days before processing.32,35
Neuropathological analysis
Fifty-micrometer serial coronal sections were
generated and analyzed from the immediate vicin-
ity of the injection site using a Leica VT100S vi-
bratome, and free-floating immunohistochemistry
was performed as previously described24,35–37 with
markers for oligodendrocytes and myelin sheaths
(mouse monoclonal anti-MBP, 1:1,000; Chemicon;
Cat. # MAB1580); dopaminergic nerve terminals
(rabbit polyclonal anti-TH, 1:5,000; Calbiochem;
Cat. # 657012); CD8+ T-cells (mouse anti-CD8, 1:
1,000; Serotec; Cat. # MCA48G); macrophages and
microglia (CD68/ED1, mouse anti-ED1, 1:1,000;
Cat. # MCA341R; IBA1, polyclonal rabbit anti-
IBA1, 1:1,000;WakoPureChemical Industries; Cat.
# 019-19741); activated macrophages, microglia,
and immune cells (mouse anti-MHC II, 1:1,000;
Serotec; Cat. # MCA46G); and Flt3L (rabbit anti-
Flt3L, 1:1,000; custom made).38 Nissl staining was
performed to assess gross histopathological features
of each brain as described previously.20 The stained
sections were photographed with a Zeiss Optical
Axioplan microscope using Axiovision Rel 4.6 and
MOSAIX software (Carl Zeiss). All histology data
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and samples were reviewed by Dr. Henry Appel-
man, M.R. Abell Professor of Surgical Pathology at
the University of Michigan.
Serum biochemistry
Collected blood was transferred to serum separa-
tion tubes (SCMicro Tube Ser-Gel PP; Biotang; Cat.
# 41.1378.005); samples were left for 30min at room
temperature to allow for blood coagulation before
centrifugation at 2,000 relative centrifugal force for
10min and immediate analysis on a VetTest 8008
serum chemistry analyzer (IDEXX Laboratories).
Circulating neutralizing antiadenovirus
antibodies
Plasma samples were heat-inactivated at 56C
for 30min and serially diluted 2-fold in minimal
essential medium (Invitrogen) containing 10%
heat-inactivated fetal bovine serum (HI-FBS). Fifty-
microliter plasma dilutions were incubated with
3·106 infectious units (iu) of first-generation Ads
expressing b-galactosidase (Ad-b-Gal, 200 iu per cell)
for 90min at 37C. A 50ll sample of the plasma/Ad-
b-Gal mix was added to wells of a 96-well plate con-
taining 1.5·104 pre-seeded HEK 293 cells and in-
cubated for 60min at 37C. Finally, an additional
50ll containing 10% FBS was added to each well,
and the cells were incubated at 37C for 20hr before
fixation with 1% glutaraldehyde in PBS (pH 7.4) and
staining with 5-bromo-4-chloro-indolyl-b-galactoside
(X-gal; Sigma).8,26 ImageJ was used to quantify the
percentage of b-Gal-positive cells in three represen-
tative images for every well. The percentages were
averaged for these wells, and the average was sub-
sequently compared with a control. The neutralizing
antibody titer for each animal is given as the recip-
rocal of the highest dilution of serum at which 50% of
maximal Ad-b-Gal-mediated transduction was in-
hibited. Serum from a pre-immunized animal was
used as a positive control, and serum from a naı¨ve
animal was used as a negative control.
DOX concentration (ng/ml) in rat plasma
Blood was collected upon euthanasia and ana-
lyzed for DOX content by the Pharmacokinetics
Core at the University of Michigan.
H&E staining
Liver and kidney tissue sections (5 lm thick)
from DOX and saline-treated rats were stained
with hematoxylin and eosin (H&E).8,39
Good laboratory practice guidelines
This study was not performed under good labo-
ratory practice guidelines.
RESULTS
Regulatable therapeutic transgene
expression in response to allometrically
scaled doses of DOX
We first assessed if allometrically scaled doses
of DOX, which would be compatible to doses al-
ready approved for use in humans, would be suffi-
cient to turn on therapeutic Flt3L expression form
theHC-Ad.TetOn.mCMV.hsFlt3L. To do this, DOX
was delivered to naı¨ve rats every 12hr via oral
gavage beginning 2 days before delivery of HC-
Ad.TetOn.mCMV.hsFlt3L and lasting for 4 weeks
(Fig. 1A)—identical to the course proposed in the
phase 1 clinical trial. At the end of the 4 weeks, rats
were perfused and the brain and other tissues were
fixed for a complete neuropathological and histo-
logical analysis to assess any potential adverse side
effects. When compared with the no DOX control,
which received equivalent volumes of water de-
livered by oral gavage twice daily (Fig. 1B), the
100mg/day equivalent (Fig. 1C), the 200mg/day
equivalent (Fig. 1D), and the 300mg/day equiva-
lent doses of DOX (Fig. 1E) revealed expression of
Flt3L detected by 3, 3¢-diaminobenzidine (DAB)
immunohistochemical analysis. This demonstrates
that each of the three most commonly used FDA-
approved doses of DOX was sufficient to turn ‘‘on’’
the therapeutic transgene under the proposedDOX
regimen.
Neuropathological analysis and systemic
effects of allometric doses of DOX
after intracranial delivery of HC-Ad
.TetOn.mCMV.hsFlt3L
Considering that the proposed clinical trial in-
volves the delivery of the therapeutic gene-delivered
therapy into the tumor cavity after the resection of
the tumor mass, it is important to assess any po-
tential neuropathological effects on normal brain
parenchyma as a result of viral transduction and
activation of therapeutic transgene expression
via DOX administration. Under the same experi-
mental design (Fig. 2A) mentioned in the previous
paragraph, a complete neuropathological analysis
of animals receiving the highest dose of DOX—
300mg/day for 1 month—was evaluated for signs
of toxicity within the brain compared with a
saline-treated control (Fig. 2B). Complete neuro-
pathological analyses of the 100mg/day equiva-
lent (Supplementary Fig. S2) and the 200mg/day
equivalent (Supplementary Fig. S3) are also shown.
Brains were processed for architectural integrity
through an evaluation of the Nissl bodies (Nissl),
white matter tracts and oligodendrocytes (MBP),
and dopaminergic nerve fibers (TH). No differences
INDUCIBLE EXPRESSION OF FLT3L IN A GBM MODEL 101
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
ic
hi
ga
n 
e-
jou
rna
l p
ack
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 12
/11
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
 
were observed when comparing the saline-treated
animals with the groups treated with 100, 200,
or 300mg/kg/day of DOX, with minor mechanical
disturbances along the needle tract resulting in a
localized increase in Nissl body prevalence. An in-
crease in the white matter bundles formed along
the needle tract in both groups was associated
with a slight decrease in the dopaminergic
nerve fiber presence. These effects can also at-
tributed to the mechanical damage caused by the
needle tract.
Immune cell infiltration of rats receiving the
300mg/day equivalent of DOX displayed a notice-
able increase in infiltrating ED1+ macrophages
(ED1), major histocompatibility complex II (MHC-
II) antigen presenting cells, CD8+ T-cells, and ac-
tivated microglia and macrophages (Iba1) when
compared with the saline-treated control animals.
Figure 1. Inducible Tet-On transactivation of Flt3L expression with allometrically scaled human doses of doxycycline (DOX). (A) Experimental design showing
a therapeutic window for DOX identical to that proposed in a pending clinical trial application to activate Flt3L transgene expression. Human-equivalent doses
of DOX approved by the FDA for use in humans (100, 200, and 300 mg/day) were allometrically scaled for use in rats and administered beginning 2 days before
treatment with the gene therapy HC-Ad vectors for 1 month. Brains from animals gavaged with water (B), 100 mg/day DOX equivalent (C), 200 mg/day DOX
equivalent (D), and 300 mg/day DOX equivalent (E) were analyzed using immunohistochemical analysis to determine Flt3L expression. Color images available
online at www.liebertpub.com/hgtb
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Animals receiving twice-daily oral gavages of
allometrically scaled doses of DOX and water were
monitored for changes in their body weight to de-
tect possible systemic adverse off-target effects
(Fig. 3A). The mean weights of animals showed a
steady increase with a similar slope when com-
pared with the controls for each experimental
group, indicative of the safety of the doses of DOX
used in this study.
One of the major limiting factors in gene ther-
apeutic strategies is the presence of circulating
neutralizing antiadenoviral antibodies in humans
who have been pre-exposed to adenoviral infec-
tions. These circulating-neutralizing anti-Ad anti-
bodies (Nabs) can hamper HC-Ad vector infection
of target cells and thus hamper therapeutic effi-
cacy. In order to assess the concentration of Nabs,
we determined the titer of neutralizing anti-
adenoviral antibodies in the plasma of rats receiv-
ing either the water control or the allometrically
scaled doses of DOX (Fig. 3B) and injected intra-
cranially with HC-Ads. Our data show no notice-
Figure 2. Neuropathological assessment of 300 mg/day DOX dose. (A) Experimental design showing the chronology of the safety study evaluating the ‘‘off-label’’
use of DOX in rats to activate the Tet-On inducible system for Flt3L. After 1 month of the 300 mg equivalent of DOX, a neuropathological analysis (B) was performed
to determine the safety of this combination in the rat brain versus the 0 DOX control. Architectural scaffolding in the brains of rats, shown by staining Nissl bodies,
reveals no gross abnormalities versus the control. Further investigation of various structural components (axons and myelin sheaths [MBP]; dopaminergic nerve
fibers [TH]) showed no differences in DOX-treated animals and controls. There appears to be an increase, however, in the immunological components of the brain,
as CD68+ macrophages (ED1), major-histocompatibility complex-II antigen presenting cells (MHC-II), CD8+ T-cells (CD8), and activated macrophages and microglia
(Iba1) revealed an increase in staining around the injection sites of DOX-treated animals when compared with controls.
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able induction of NAbs in rats receiving in-
trastriatal delivery of HC-Ads.
The use of DOX as the transcriptional activator
of the Tet-On-inducible system ensures an added
layer of safety in our gene therapeutic approach by
allowing physicians to turn ‘‘on’’ and ‘‘off ’’ gene ex-
pression upon addition or withdrawal of DOX, re-
spectively. Quantifying the concentration of DOX
in the plasma could allude to its efficacy to activate
the expression of the therapeutic transgene, that
is, Flt3L. To this end, we collected blood from rats
5 hr after receiving their morning administration
of DOX, isolated the plasma, and quantified the
circulating concentration of DOX. Rats receiving
allometrically scaled doses of 100, 200, and 300mg/
day showed DOX concentrations of (mean – stan-
dard error) 462.75– 107.83, 585.25 –351.91, and
1,024 –16.80ng/ml, respectively (Fig. 3C).
Figure 3. Absence of circulating anti-Ad antibodies post-surgery in rats receiving DOX. The body weight of Lewis rats receiving DOX was monitored during
the course of the safety study and compared with a control rat receiving water (A). Blood from rats treated for 1 month with allometrically scaled doses of DOX
was collected via cardiac puncture before perfusion and fixation and processed for (B) neutralizing antiadenovirus antibodies, which were quantified in the
sera of rats treated with allometric equivalents of DOX in the safety analysis. (C) DOX concentration 5 hr after latest dosing for each dose. (D) A
histopathological analysis of organs associated with metabolism and detoxification of DOX and its metabolites—the liver and kidneys—showed no gross
changes in animals treated with the control or the 100, 200, or 300 mg/day DOX equivalent. Scale bars for liver and kidney histopathology: 2lm.
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The liver and kidneys are the most commonly
implicated sites associatedwith themetabolismand
elimination of DOX and its potential metabolites,40
and are also the most commonly implicated organs
in viral sequestration.41,42 We examined the livers
and kidneys of control and DOX-treated animals
after processing and staining the tissue with H&E
for signs of systemic toxicities (Fig. 3D). Livers from
all animals revealed healthy hepatocytes and kid-
neys revealed normal nephrons in all the groups
with no indication of inflammation or toxicities.
Systemic toxicitieswere further analyzed through
a complete hematological and serum biochemical
analysis (Supplementary Table S1) in rats from all
the groups before and after the 4-week treatment
with allometrically scaled doses of DOX. All pa-
rameters were comparedwith control water-treated
animals. No change in the cellular components of
the blood was noted through complete blood counts
for animals receiving DOX when compared with
the water-treated controls, nor were there any
significant changes in important enzymes involved
in liver (ALT, ALKP, AST) and kidney (BUN, CRE)
physiology.
Efficacy of HC-Ad.TK + HC-Ad.TetOn.mCMV
.hsFlt3L in response to allometrically scaled
doses of DOX in a transplantable rat glioma
model
To examine the efficacy associated with the dif-
ferent allometrically scaled doses of DOX, the 200
and 300mg/daywere used as the variable in a set of
survival analyses in rats bearing syngeneic CNS-1
tumors, receiving the HC-Ad-mediated TK/Flt3L
combined gene therapy in conjunction with 10 days
of GCV administration and 4 weeks of twice-daily
administration of DOX (Fig. 4A).
We observed a significant survival advantage
when using the allometrically scaled 300mg/day
humanequivalent dose ofDOXwhen comparedwith
the 200mg/day equivalent (p=0.0304) (Fig. 4B).
Over 62% of rats receiving the 300mg/day equiva-
lent dose of DOX survived the initial tumor threat,
compared with only 25% of rats receiving the
200mg/day equivalent. Previous survival analyses
were conducted by our group using DOX chow at a
concentration of 2,000 parts per million (ppm) con-
sumed ad libitum (685.2mg/day) by tumor-bearing
rats treated with the combined gene therapy,9,43
which showed a comparable overall survival of rats
(*70%). Our results indicate that there is no sur-
vival benefit in escalating the recommended doses of
DOX past 300mg/day, but shows that there is a
significant survival advantage for the 300mg/day
dosage over the 200mg/day dosage.
To study tumor regression after delivery of
HC-Ad.TK + HC-Ad.TetOn.mCMV.hsFlt3L, we
performed a neuropathological analysis compar-
ing the brains of moribund saline-treated control
animals to the brains of rats 90 days after receiv-
ing the combined TK/Flt3L therapy (Fig. 4C).
Saline-treated controls show ipsilateral hemi-
spheres that are filledwithNissl bodies, alongwith
infiltrating immune cells, such as macrophages
(ED1), MHC-II-expressing cells (MHC-II), CD8+
T-cells (CD8), and activated microglia and mac-
rophages (Iba1). The tumor mass completely dis-
placed the white matter tracts (MBP) and
dopaminergic nerve terminals (TH) without any
evidence of the Flt3L or TK transgene expression
(saline was delivered to these animals in place of
the HC-Ad vectors). Tumor-bearing rats analyzed
90 days after gene therapy showed little to no
evidence of any disturbance near the site of tumor
implantation or viral therapy. Nissl stain showed
no remnants of either the tumor or the injection
needle tract. A slight increase in the density of
white matter tracts (MBP) surrounding the in-
jection site indicates continued repair of the ear-
lier mechanical damage and regression of a large
tumor mass. Dopaminergic nerve terminals (TH)
are slightly displaced in the direct vicinity of the
brain tumor implantation. There were still rem-
nants of ED1+ macrophages where the injection
needle penetrated the corpus callosum, whereas
MHC-II and CD8 cells were scarcely present. Iba1
showed slight activation of microglia and macro-
phages along needle tract made from the tumor
implantation and gene therapy. Finally, the TK
and Flt3L transgenes delivered by the HC-Ad
vector were detected 90 days after gene therapy in
normal parenchyma in the ipsilateral hemisphere
(Fig. 4C).
HC-Ad.TK + HC-Ad.TetOn.mCMV.hsFlt3L gene
therapy prevents tumor recurrence in a rat
glioma model in response to treatment
with 300mg/kg of DOX
Long-term-surviving rats from the 300mg/day
DOX equivalent group discussed in the previous
section were re-challenged 90 days after gene
therapy with a second tumor threat implanted
into the contralateral hemisphere (Fig. 5A). Fifty
percent of recurrent brain tumors were elimi-
nated, indicating the development of a robust
immunologicalmemory in response to the immune-
stimulatory gene therapeutic approach mediated
by DOX-induced Flt3L expression (Fig. 5B).
Figure 5C shows the neuropathological analysis
of rats that cleared a primary brain tumor threat
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Figure 4. In vivo efficacy of 300 mg/day DOX dose in tumor-bearing rats. (A) Experimental design showing the chronology of a survival analysis experiment,
starting with the implantation of 3,000 CNS-1 tumor cells into the right striatum (ipsilateral hemisphere) of male Lewis rats 6 days before gene therapy. DOX was
administered twice daily via oral gavage beginning 2 days before the gene therapy using the human equivalent doses of 200 or 300 mg/day in rats and lasting
for 1 month. Ganciclovir (GCV) was administered twice daily via intraperitoneal injection (7 mg/kg) beginning on the day of gene therapy and lasting for 10 days.
(B) Kaplan–Meier survival analysis of Lewis rats receiving gene therapy and human equivalent doses of DOX. (C) A neuropathological and transgene
expression analysis in rats receiving no gene therapy (saline control, left panel), and rats receiving the gene therapy along with the human equivalent of
300 mg/day of DOX for 1 month; 90 days after gene therapy. Architectural scaffolding in the brains of rats, shown by staining Nissl bodies, reveals the complete
invasion by tumor cells of the striata of control rats, whereas minor evidence of intervention can be seen in the treated rats. Other structural components
showed a similar pattern, with axons and myelin sheaths (MBP), and dopaminergic nerve fibers (TH) completely displaced by the tumor mass, with no change
to the treated animals. Immunological components, like CD68+ macrophages (ED1), major-histocompatibility complex-II antigen presenting cells (MHC-II), CD8+
T-cells (CD8), and activated macrophages and microglia (Iba1) are shown throughout the tumor and surrounding parenchyma, whereas only minor remnants of
these cell types can be found in the treated animals 90 days after receiving gene therapy. Additionally, evidence of the Flt3L and TK transgenes was detected
using DAB immunohistochemical analysis in rats treated with the gene therapy. Scale bars: 1,000lm for full brain sections, 200 lm for 4· images, 20 lm for 40·
images, and 5lm for 100· insets.
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Figure 5. Adaptive immunity eliminates recurrent brain tumors in rats with 300 mg/day equivalent of DOX. (A) Experimental design showing the chronology of a
survival analysis experiment (see Fig. 4). Long-term survivors from this experiment were re-challenged 90 days after the initial surgery with 3,000 CNS-1 cells
implanted into the contralateral striata. (B) Kaplan–Meier survival analysis of rechallenged Lewis rats receiving gene therapy and human equivalent doses of DOX.
(C) A complete neuropathological immunohistochemical analysis was performed on survivors of both the initial brain tumor and survivors were then re-challenged,
simulating a recurrent GBM. These animals responded to the initial gene therapeutic approach by developing an adaptive immunological response that cleared
new tumor threats. Neuropathological analysis was performed on surviving rats to evaluate the integrity of critical brain components following primary (ipsilateral
hemisphere) and secondary (contralateral hemisphere). Staining for Nissl bodies showed slight mechanical aberrations from the needle tracts, with more intense
localized staining in the more recent re-challenge tumor than the primary tumor implantation and subsequent gene therapy. MBP shows an increased density of
axonal bundles surrounding the injection sites in both hemispheres, whereas TH staining showed slight displacement of dopaminergic nerve fibers in the vicinity of
the injection sites. Immunological components (CD68+ macrophages [ED1], major-histocompatibility complex-II antigen presenting cells [MHC-II], CD8+ T-cells
[CD8], and activated macrophages and microglia [Iba1]) all revealed an increase in staining around the injection site for the secondary tumor with lesser staining
surrounding the earlier tumor challenge. Finally, the Flt3L transgene was detected in the hemisphere receiving the gene therapy several months after treatment.
Scale bars: 1,000lm for full brain sections, 200lm for midmagnification images, 20lm for the highest magnification images, and 5lm for 100· insets.
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(Ipsilateral Hemisphere) through the gene thera-
peutic approach with the allometrically scaled
300mg/day dose of DOX, and subsequently elimi-
nated a ‘‘recurrent’’ brain tumor challenge (con-
tralateral hemisphere) without any additional
treatment. Nissl shows largely unaffected gross tis-
sue morphology with areas of increased cell density
near needle tract from delivery of the re-challenge
tumor into the contralateral hemisphere 1 month
after injection. The ipsilateral hemisphere shows no
evidence of heightened cell density 4 months after
gene therapy. Similarly, DAB immunohistochemical
analysis on free-floating sections shows increased
MBP staining of axonal bundles surrounding the site
of tumor re-challenge, indicative of oligodendrocyte
activation. Meanwhile, the ipsilateral hemisphere
shows little indication of alterations in the white
matter surrounding the injection sites. These sites
are identified only through the presence of hemo-
siderin staining, a result of macrophage phago-
cytosis of the iron-containing heme cofactor of red
blood cells caused by mechanical damage of the
needle. TH staining shows highly localized dis-
placement of dopaminergic nerve endings along
the needle tract in both the contralateral and ip-
silateral hemispheres.
The immunological components of both striata
show similar patterns, with ED1, MHC-II, CD8,
and Iba1 immunohistochemical analyses showing
increased levels of infiltrating immune cells at the
site of the most recent tumor implantation (con-
tralateral hemisphere), and lower levels of these
markers in the ipsilateral hemisphere. Particu-
larly noteworthy is the relatively large population
of CD8+ T-cells in the contralateral hemisphere
of animals that recently eliminated ‘‘recurrent’’
brain tumors.
Finally, theFlt3L transgenewas detected in the
ipsilateral hemisphere of rats cured of primary
and secondary brain tumors using the combined
gene therapeutic approach, showing the enhanced
stability of transgenes via the HC-Ad platform for
long periods of time.9,44 The TK transgene was not
detected in the section analyzed. This transgene
does not persist in surviving animals, as a large
number of cells transduced with TK are tumor
cells eliminated in the process of GCV-induced cell
death.
A complete hematological and serum biochemical
analysis was run on animals surviving the second-
ary tumor and compared with blood drawn from a
long-term surviving animal harvested 90 days
post-injection (dpi) (Supplementary Table S2).
These data show no significant change in any of the
cellular components of the blood, or any of the
proteins associated with normal liver and kidney
health.
DISCUSSION
Our group has pioneered the development of
regulatable HC-Ads for GBM immune-mediated
gene therapy.9,43,44 We previously constructed
and characterized a novel HC-Ad vector platform
using a modified tetracycline-dependent inducible
system (TetOn) that enables efficient and tightly
regulated transgene expression in vitro and also
in the central nervous system in vivo.10,11,31,45 The
use of DOX as the transcriptional activator of the
Tet-On-inducible system ensures an added layer
of safety in the gene therapeutic approach pro-
posed by allowing therapeutic transgene expres-
sion, that is, Flt3L to be turned ‘‘on’’ or ‘‘off’’ in the
presence or absence of DOX, respectively, and in
line with medical need.
We also previously demonstrated the thera-
peutic efficacy and high safety profile of the com-
bined, conditional cytotoxic/immune stimulatory
gene therapy strategy using these regulatable
HC-Ads (HC-Ad-TK + HC-Ad-TetOn-Flt3L) in
syngeneic, orthotopic rat models of GBM.9 Ad-
ditionally, as a requirement before initiating a
phase 1 clinical trial for GBM, we performed
a dose-escalation and biodistribution study of
HC-Ad-TK + HC-Ad-TetOn-Flt3L to assess the
maximum tolerated dose (MTD) of these viral
vectors in the brain in vivo.44 We found that dose
to be 1 · 109 viral particles (vp). Using real-time
quantitative PCR we did not observe evidence of
biodistribution of vector genomes to peripheral
organs, behavioral testing revealed no abnormal-
ities, and serum biochemistry was also normal.9,44
As a prelude to the phase I clinical trial using this
vector platform, we needed to examine the amount
of DOX required to induce transgene activation
from the TetOn transactivation system. In previous
preclinical studies testing the therapeutic efficacy of
HC-Ad-TK + HC-Ad-TetOn-Flt3L, rat chow con-
taining DOX at a concentration of 2,000ppm was
provided ad libitum to animals for a period of 1
month, which is equivalent to 685.2mg/day.9,44 Al-
though our results showed an increase in survival
rate for animals treated with the combined gene
therapy versus animals injected with saline, con-
verting this DOX concentration to human equiva-
lents yielded doses (685.2mg/day) that had never
been tested in humans and thus their safety could
come into question. To address this, we elected
to use the three most common doses of DOX ap-
proved by the FDA for use in humans, 100, 200, and
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300mg/day, assuming a body weight of 70kg, and
assessed their efficacy at inducing tumor regression
and immunological memory in a syngeneic GBM
model in rodents. The use of DOX to induce trans-
gene expression via a TetOn transactivation sys-
tem is not currently approved for use in humans;
this study proposes an ‘‘off-label’’ application for this
drug.
Our data suggest that FDA-approved doses of
DOX can successfully induce expression of the
Flt3L transgene without eliciting systemic toxi-
cities (Fig. 3). Monitoring of post-surgery body
weight shows a steady increase in weight over
time for both DOX-receiving animals and con-
trols. A histopathological analysis of the liver and
kidneys of rats receiving HC-Ad-TK + HC-Ad-
TetOn-Flt3L reveals no gross morphological
changes; furthermore, staining of the tissues with
H&E shows normal nephrons and hepatocytes in
all three tested DOX doses when compared with
control animals. Neutralizing antibodies have not
been detected in the circulation of GBM-bearing
animals treated with HC-Ad-TetOn-Flt3L + HC-
Ad-TK delivered into the brain tumor mass. Al-
though opsonizing factors could direct the HC-Ad
vector to phagocytes,46 diminishing therapeutic
transgene expression, previous work from our
group has not encountered this possibility after
delivery of the vectors into either the normal
brain parenchyma, or into a tumor mass growing
within the brain, even in the presence of a
systemic immunization against the adenovirus
vectors.5,11,30–32 In addition, hematological and
biochemical parameters were all normal in both
DOX-treated animals and controls (Supplemen-
tary Table S1).
Having determined that allometrically scaled
doses of DOX approved by the FDA for use in
human patients were able to turn on therapeutic
transgene expression from HC-Ad-TetOn-Flt3L,
we set out to examine their therapeutic efficacy in
a tumor-bearing animal model of GBM in prepa-
ration for a phase I clinical trial. Using the 200
and 300mg/day human equivalent doses of DOX,
we analyzed the survival rates for tumor-bearing
animals. The data indicate a significant survival
advantage of the 300mg/day DOX dose over
the 200mg/day dose (Fig. 4B). The survival rate
of animals in the 300mg/day cohort (*62%) was
comparable to the survival rate (*70%) of ani-
mals in previous preclinical experiments that
received doses of DOX higher than those ap-
proved by the FDA.9,44 Furthermore, we observed
no neuropathological adverse side effects as a
result of HC-Ad transduction or transgene acti-
vation. These results indicate that these allome-
trically equivalent doses of DOX are effective to
evoke tumor regression and that substantially
higher DOX doses do not confer a meaningful
survival advantage over the FDA-approved
doses.
Human GBM is characterized by a high rate of
tumor recurrence, despite an aggressive current
standard of care, including gross tumor resection
whenever possible, ionizing radiation treatments,
and adjuvant chemotherapy. For this reason, it is
critical to develop a therapy that not only over-
comes the initial tumor burden, but also provides a
lasting efficacy against tumor recurrence. Thus, we
next demonstrated that the allometrically scaled
doses of DOX elicited expression of sufficient levels
of Flt3L to enable mounting effective anti-GBM
immunological memory. Long-term surviving ani-
mals were re-challenged with tumor cells in the
contralateral hemisphere 90 days after initial ad-
ministration of the combined gene therapy (Fig. 5A)
and did not receive any further treatment. By the
end of the 120-day trial, half of the re-challenged
animals rejected the second tumor, indicating the
stimulation of immunological memory (Fig. 5B).
These data provide strong support for implementing
phase I clinical trial for GBM using HC-Ad-TK +
HC-Ad-TetOn-Flt3L as an effective and safe thera-
peutic gene delivery platform, which has the added
safety feature of DOX-mediated regulated trans-
gene expression. This work has significant transla-
tional relevance for our own ongoing clinical trial
as well as for other researchers interested in im-
plementing the Tet-On transcriptional activation-
dependent expression of therapeutic transgenes
within the brain.
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